Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Exceptional Responses After Cessation of Therapy With Alkylating Agents for Pancreatic Neuroendocrine Tumors.

Wu YL, Raj N, Reidy-Lagunes D.

Pancreas. 2020 Jan;49(1):e14-e16. doi: 10.1097/MPA.0000000000001451. No abstract available.

PMID:
31856101
2.

Lack of Availability and Efficacy of Phase I and Basket Trials for Patients with Gastrointestinal Cancers.

Agarwal R, Cangemi NA, Epstein AS, Harding J, Reidy-Lagunes D, Saltz LB.

J Natl Cancer Inst. 2019 Dec 13. pii: djz228. doi: 10.1093/jnci/djz228. [Epub ahead of print]

PMID:
31834379
3.

Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors.

Hauser H, Gerson DS, Reidy-Lagunes D, Raj N.

Curr Treat Options Oncol. 2019 Nov 27;20(12):87. doi: 10.1007/s11864-019-0690-x. Review.

PMID:
31776785
4.

Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.

Cercek A, Boerner T, Tan BR, Chou JF, Gönen M, Boucher TM, Hauser HF, Do RKG, Lowery MA, Harding JJ, Varghese AM, Reidy-Lagunes D, Saltz L, Schultz N, Kingham TP, D'Angelica MI, DeMatteo RP, Drebin JA, Allen PJ, Balachandran VP, Lim KH, Sanchez-Vega F, Vachharajani N, Majella Doyle MB, Fields RC, Hawkins WG, Strasberg SM, Chapman WC, Diaz LA Jr, Kemeny NE, Jarnagin WR.

JAMA Oncol. 2019 Oct 31. doi: 10.1001/jamaoncol.2019.3718. [Epub ahead of print]

PMID:
31670750
5.

PD-1 Blockade in Advanced Adrenocortical Carcinoma.

Raj N, Zheng Y, Kelly V, Katz SS, Chou J, Do RKG, Capanu M, Zamarin D, Saltz LB, Ariyan CE, Untch BR, O'Reilly EM, Gopalan A, Berger MF, Olino K, Segal NH, Reidy-Lagunes DL.

J Clin Oncol. 2020 Jan 1;38(1):71-80. doi: 10.1200/JCO.19.01586. Epub 2019 Oct 23.

PMID:
31644329
6.

Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines'.

Alvarez MJ, Yan P, Alpaugh ML, Bowden M, Sicinska E, Zhou CW, Karan C, Realubit RB, Mundi PS, Grunn A, Jäger D, Chabot JA, Fojo AT, Oberstein PE, Hibshoosh H, Milsom JW, Kulke MH, Loda M, Chiosis G, Reidy-Lagunes DL, Califano A.

Nat Genet. 2019 Oct;51(10):1427-1428. doi: 10.1038/s41588-019-0509-5. No abstract available.

PMID:
31548719
7.

Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan.

Reidy-Lagunes D, Pandit-Taskar N, O'Donoghue JA, Krebs S, Staton KD, Lyashchenko SK, Lewis JS, Raj N, Gönen M, Lohrmann C, Bodei L, Weber WA.

Clin Cancer Res. 2019 Dec 1;25(23):6939-6947. doi: 10.1158/1078-0432.CCR-19-1026. Epub 2019 Aug 22.

PMID:
31439583
8.

A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma.

Xie H, Yin J, Shah MH, Menefee ME, Bible KC, Reidy-Lagunes D, Kane MA, Quinn DI, Gandara DR, Erlichman C, Adjei AA.

Invest New Drugs. 2019 Aug;37(4):755-762. doi: 10.1007/s10637-019-00797-1. Epub 2019 Jun 6.

PMID:
31172443
9.

Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition.

Allen A, Qin ACR, Raj N, Wang J, Uddin S, Yao Z, Tang L, Meyers PA, Taylor BS, Berger MF, Yaeger R, Reidy-Lagunes D, Pratilas CA.

PLoS One. 2019 Jun 3;14(6):e0217399. doi: 10.1371/journal.pone.0217399. eCollection 2019.

10.

Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer.

Ng SY, Colborn KL, Cambridge L, Cercek A, Reidy-Lagunes DL, Segal N, Stadler Z, Saltz LB, Paty PB, Guillem J, Weiser MR, Nash G, Garcia-Aguilar J, Goodman KA.

Clin Colorectal Cancer. 2019 Sep;18(3):167-174. doi: 10.1016/j.clcc.2019.04.001. Epub 2019 Apr 6.

PMID:
31104990
11.

Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability.

Raj N, Shah R, Stadler Z, Mukherjee S, Chou J, Untch B, Li J, Kelly V, Saltz LB, Mandelker D, Ladanyi M, Berger MF, Klimstra DS, Reidy-Lagunes D, Osoba M.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00267. Epub 2018 Apr 19.

12.

Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.

Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Mandelker D, Middha S, Hechtman J, Zehir A, Dubard-Gault M, Tran C, Stewart C, Sheehan M, Penson A, DeLair D, Yaeger R, Vijai J, Mukherjee S, Galle J, Dickson MA, Janjigian Y, O'Reilly EM, Segal N, Saltz LB, Reidy-Lagunes D, Varghese AM, Bajorin D, Carlo MI, Cadoo K, Walsh MF, Weiser M, Aguilar JG, Klimstra DS, Diaz LA Jr, Baselga J, Zhang L, Ladanyi M, Hyman DM, Solit DB, Robson ME, Taylor BS, Offit K, Berger MF, Stadler ZK.

J Clin Oncol. 2019 Feb 1;37(4):286-295. doi: 10.1200/JCO.18.00283. Epub 2018 Oct 30. Erratum in: J Clin Oncol. 2019 Apr 10;37(11):942.

13.

Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors.

Pulvirenti A, Rao D, Mcintyre CA, Gonen M, Tang LH, Klimstra DS, Fleisher M, Ramanathan LV, Reidy-Lagunes D, Allen PJ.

HPB (Oxford). 2019 May;21(5):612-618. doi: 10.1016/j.hpb.2018.09.016. Epub 2018 Oct 23.

PMID:
30366884
14.

DAXX Mutation Status of Embolization-Treated Neuroendocrine Tumors Predicts Shorter Time to Hepatic Progression.

Ziv E, Rice SL, Filtes J, Yarmohammadi H, Boas FE, Erinjeri JP, Petre EN, Brody LA, Brown KT, Covey AM, Getrajdman GI, Maybody M, Raj N, Sofocleous CT, Solomon SB, Reidy-Lagunes D.

J Vasc Interv Radiol. 2018 Nov;29(11):1519-1526. doi: 10.1016/j.jvir.2018.05.023. Epub 2018 Oct 19.

PMID:
30342802
15.

Corrigendum to "Antidepressants appear safe in patients with carcinoid tumor: Results of a retrospective review" [YEJSO 44 (6) (June 2018) 744-749].

Isenberg-Grzeda E, MacGregor M, Bergel A, Eagle S, Espi Forcen F, Mehta R, Matsoukas K, Wills J, Reidy-Lagunes D, Alici Y.

Eur J Surg Oncol. 2018 Sep;44(9):1453. doi: 10.1016/j.ejso.2018.06.002. Epub 2018 Jun 20. No abstract available.

16.

A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors.

Alvarez MJ, Subramaniam PS, Tang LH, Grunn A, Aburi M, Rieckhof G, Komissarova EV, Hagan EA, Bodei L, Clemons PA, Dela Cruz FS, Dhall D, Diolaiti D, Fraker DA, Ghavami A, Kaemmerer D, Karan C, Kidd M, Kim KM, Kim HC, Kunju LP, Langel Ü, Li Z, Lee J, Li H, LiVolsi V, Pfragner R, Rainey AR, Realubit RB, Remotti H, Regberg J, Roses R, Rustgi A, Sepulveda AR, Serra S, Shi C, Yuan X, Barberis M, Bergamaschi R, Chinnaiyan AM, Detre T, Ezzat S, Frilling A, Hommann M, Jaeger D, Kim MK, Knudsen BS, Kung AL, Leahy E, Metz DC, Milsom JW, Park YS, Reidy-Lagunes D, Schreiber S, Washington K, Wiedenmann B, Modlin I, Califano A.

Nat Genet. 2018 Jul;50(7):979-989. doi: 10.1038/s41588-018-0138-4. Epub 2018 Jun 18.

17.

Antidepressants appear safe in patients with carcinoid tumor: Results of a retrospective review.

Isenberg-Grzeda E, MacGregor M, Bergel A, Eagle S, Espi Forcen F, Mehta R, Matsoukas K, Wills J, Reidy-Lagunes D, Alici Y.

Eur J Surg Oncol. 2018 Jun;44(6):744-749. doi: 10.1016/j.ejso.2018.03.010. Epub 2018 Mar 21. Erratum in: Eur J Surg Oncol. 2018 Sep;44(9):1453.

18.
19.

Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.

Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR.

J Nucl Med. 2018 Jan;59(1):66-74. doi: 10.2967/jnumed.117.202275. Epub 2017 Oct 12. No abstract available.

20.

MENIN loss as a tissue-specific driver of tumorigenesis.

Li JWY, Hua X, Reidy-Lagunes D, Untch BR.

Mol Cell Endocrinol. 2018 Jul 5;469:98-106. doi: 10.1016/j.mce.2017.09.032. Epub 2017 Sep 28. Review.

PMID:
28965973
21.

Commentary: Somatostatin analogs-How we choose, and why.

Reidy-Lagunes D, Raj N, Saltz L.

Semin Oncol. 2017 Apr;44(2):157-158. doi: 10.1053/j.seminoncol.2017.08.001. Epub 2017 Aug 4. No abstract available.

PMID:
28923214
22.

Biodistribution and Dosimetry of 18F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies.

Pandit-Taskar N, Zanzonico P, Staton KD, Carrasquillo JA, Reidy-Lagunes D, Lyashchenko S, Burnazi E, Zhang H, Lewis JS, Blasberg R, Larson SM, Weber WA, Modak S.

J Nucl Med. 2018 Jan;59(1):147-153. doi: 10.2967/jnumed.117.193169. Epub 2017 Jul 13.

23.

O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.

Raj N, Klimstra DS, Horvat N, Zhang L, Chou JF, Capanu M, Basturk O, Do RKG, Allen PJ, Reidy-Lagunes D.

Pancreas. 2017 Jul;46(6):758-763. doi: 10.1097/MPA.0000000000000842.

24.

Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.

Reidy-Lagunes DL, Lung B, Untch BR, Raj N, Hrabovsky A, Kelly C, Gerst S, Katz S, Kampel L, Chou J, Gopalan A, Saltz LB.

Oncologist. 2017 Sep;22(9):1102-1106. doi: 10.1634/theoncologist.2016-0459. Epub 2017 May 30.

25.

Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies.

Cercek A, Boucher TM, Gluskin JS, Aguiló A, Chou JF, Connell LC, Capanu M, Reidy-Lagunes D, D'Angelica M, Kemeny NE.

J Surg Oncol. 2016 Nov;114(6):655-663. doi: 10.1002/jso.24399. Epub 2016 Aug 26.

26.

Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.

Raj N, Valentino E, Capanu M, Tang LH, Basturk O, Untch BR, Allen PJ, Klimstra DS, Reidy-Lagunes D.

Pancreas. 2017 Mar;46(3):296-301. doi: 10.1097/MPA.0000000000000735.

27.

Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min.

Cercek A, Park V, Yaeger R, Reidy-Lagunes D, Kemeny NE, Stadler ZK, Segal NH, Varghese A, Saltz LB.

J Oncol Pract. 2016 May;12(5):e548-53. doi: 10.1200/JOP.2015.008417. Epub 2016 Apr 12.

28.

Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels.

Stadler ZK, Battaglin F, Middha S, Hechtman JF, Tran C, Cercek A, Yaeger R, Segal NH, Varghese AM, Reidy-Lagunes DL, Kemeny NE, Salo-Mullen EE, Ashraf A, Weiser MR, Garcia-Aguilar J, Robson ME, Offit K, Arcila ME, Berger MF, Shia J, Solit DB, Saltz LB.

J Clin Oncol. 2016 Jun 20;34(18):2141-7. doi: 10.1200/JCO.2015.65.1067. Epub 2016 Mar 28.

29.

Cytological features contributing to the misclassification of pancreatic neuroendocrine tumors.

Sigel C, Reidy-Lagunes D, Lin O, Basturk O, Aggarwal G, Klimstra DS, Tang L.

J Am Soc Cytopathol. 2016 Sep - Oct;5(5):266-276. doi: 10.1016/j.jasc.2016.01.001. Epub 2016 Feb 2.

PMID:
31042503
30.

Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.

Raj N, Reidy-Lagunes D.

Hematol Oncol Clin North Am. 2016 Feb;30(1):119-33. doi: 10.1016/j.hoc.2015.09.005. Epub 2015 Oct 23. Review.

31.

Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study.

Sadot E, Reidy-Lagunes DL, Tang LH, Do RK, Gonen M, D'Angelica MI, DeMatteo RP, Kingham TP, Groot Koerkamp B, Untch BR, Brennan MF, Jarnagin WR, Allen PJ.

Ann Surg Oncol. 2016 Apr;23(4):1361-70. doi: 10.1245/s10434-015-4986-1. Epub 2015 Nov 23.

32.

New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.

Phan AT, Kunz PL, Reidy-Lagunes DL.

Clin Adv Hematol Oncol. 2015 May;13(5 Suppl 5):1-18; quiz 1 p following 18.

PMID:
26430956
33.
34.

Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.

Hobday TJ, Qin R, Reidy-Lagunes D, Moore MJ, Strosberg J, Kaubisch A, Shah M, Kindler HL, Lenz HJ, Chen H, Erlichman C.

J Clin Oncol. 2015 May 10;33(14):1551-6. doi: 10.1200/JCO.2014.56.2082. Epub 2014 Dec 8.

35.

Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors.

Castellano D, Grande E, Valle J, Capdevila J, Reidy-Lagunes D, O'Connor JM, Raymond E.

Cancer Chemother Pharmacol. 2015 Jun;75(6):1099-114. doi: 10.1007/s00280-014-2642-2. Epub 2014 Dec 6. Review.

PMID:
25480314
36.

Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.

Cercek A, Shia J, Gollub M, Chou JF, Capanu M, Raasch P, Reidy-Lagunes D, Proia DA, Vakiani E, Solit DB, Saltz LB.

Clin Colorectal Cancer. 2014 Dec;13(4):207-12. doi: 10.1016/j.clcc.2014.09.001. Epub 2014 Sep 21.

37.

Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.

Raj N, Reidy-Lagunes D.

Pancreas. 2014 Nov;43(8):1185-9. doi: 10.1097/MPA.0000000000000232. Review.

PMID:
25333401
38.

False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer.

Litvak A, Cercek A, Segal N, Reidy-Lagunes D, Stadler ZK, Yaeger RD, Kemeny NE, Weiser MR, Pessin MS, Saltz L.

J Natl Compr Canc Netw. 2014 Jun;12(6):907-13.

PMID:
24925201
39.

Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer.

Cercek A, Goodman KA, Hajj C, Weisberger E, Segal NH, Reidy-Lagunes DL, Stadler ZK, Wu AJ, Weiser MR, Paty PB, Guillem JG, Nash GM, Temple LK, Garcia-Aguilar J, Saltz LB.

J Natl Compr Canc Netw. 2014 Apr;12(4):513-9.

40.

Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors.

Untch BR, Bonner KP, Roggin KK, Reidy-Lagunes D, Klimstra DS, Schattner MA, Fong Y, Allen PJ, D'Angelica MI, DeMatteo RP, Jarnagin WR, Kingham TP, Tang LH.

J Gastrointest Surg. 2014 Mar;18(3):457-62; discussion 462-3. doi: 10.1007/s11605-014-2456-x. Epub 2014 Jan 22.

PMID:
24448999
41.

Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.

Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem JG, Temple LK, Paty PB, Saltz LB.

J Clin Oncol. 2014 Feb 20;32(6):513-8. doi: 10.1200/JCO.2013.51.7904. Epub 2014 Jan 13.

42.

Factors affecting periprocedural morbidity and mortality and long-term patient survival after arterial embolization of hepatic neuroendocrine metastases.

Sofocleous CT, Petre EN, Gonen M, Reidy-Lagunes D, Ip IK, Alago W, Covey AM, Erinjeri JP, Brody LA, Maybody M, Thornton RH, Solomon SB, Getrajdman GI, Brown KT.

J Vasc Interv Radiol. 2014 Jan;25(1):22-30; quiz 31. doi: 10.1016/j.jvir.2013.09.013.

PMID:
24365504
43.

In reply.

Yao J, Reidy Lagunes D, Kulke MH.

Oncologist. 2013;18(11):1240-1. doi: 10.1634/theoncologist.2013-0242. No abstract available.

44.

A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.

Abou-Alfa GK, Capanu M, O'Reilly EM, Ma J, Chou JF, Gansukh B, Shia J, Kalin M, Katz S, Abad L, Reidy-Lagunes DL, Kelsen DP, Chen HX, Saltz LB.

J Hepatol. 2014 Feb;60(2):319-24. doi: 10.1016/j.jhep.2013.09.008. Epub 2013 Sep 14.

45.

A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.

Lee JK, Capanu M, O'Reilly EM, Ma J, Chou JF, Shia J, Katz SS, Gansukh B, Reidy-Lagunes D, Segal NH, Yu KH, Chung KY, Saltz LB, Abou-Alfa GK.

Br J Cancer. 2013 Aug 20;109(4):915-9. doi: 10.1038/bjc.2013.432. Epub 2013 Jul 30.

46.

Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer.

Cercek A, Siegel CL, Capanu M, Reidy-Lagunes D, Saltz LB.

Clin Colorectal Cancer. 2013 Sep;12(3):163-7. doi: 10.1016/j.clcc.2013.04.007. Epub 2013 Jul 17.

PMID:
23871161
47.

Consensus guidelines for the management and treatment of neuroendocrine tumors.

Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC; North American Neuroendocrine Tumor Society.

Pancreas. 2013 May;42(4):557-77. doi: 10.1097/MPA.0b013e31828e34a4.

48.

The management of extrapulmonary poorly differentiated (high-grade) neuroendocrine carcinomas.

Smith J, Reidy-Lagunes D.

Semin Oncol. 2013 Feb;40(1):100-8. doi: 10.1053/j.seminoncol.2012.11.011. Review.

PMID:
23391117
49.

Systemic therapy for advanced pancreatic neuroendocrine tumors: an update.

Reidy-Lagunes DL.

J Natl Compr Canc Netw. 2012 Jun 1;10(6):777-83. Review.

PMID:
22679119
50.

Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors.

Balagula Y, Rosen A, Tan BH, Busam KJ, Pulitzer MP, Motzer RJ, Feldman DR, Konner JA, Reidy-Lagunes D, Myskowski PL, Lacouture ME.

Cancer. 2012 Oct 15;118(20):5078-83. doi: 10.1002/cncr.27505. Epub 2012 Mar 21.

Supplemental Content

Loading ...
Support Center